A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis
Phase of Trial: Phase II
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Lyophilised Oxalobacter formigenes (Primary)
- Indications Primary hyperoxaluria
- Focus Therapeutic Use
- Sponsors OxThera
- 28 Apr 2017 Planned number of patients changed from 8 to 9.
- 26 Sep 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2018.
- 26 Sep 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2018.